Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo

P. Storti, V. Marchica, I. Airoldi, G. Donofrio, E. Fiorini, V. Ferri, D. Guasco, K. Todoerti, R. Silbermann, J. L. Anderson, W. Zhao, L. Agnelli, M. Bolzoni, E. Martella, C. Mancini, N. Campanini, D. M. Noonan, P. G. Petronini, A. Neri, F. AversaG. David Roodman, N. Giuliani

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Galectin-1 (Gal-1) is involved in tumoral angiogenesis, hypoxia and metastases. Actually the Gal-1 expression profile in multiple myeloma (MM) patients and its pathophysiological role in MM-induced angiogenesis and tumoral growth are unknown. In this study, we found that Gal-1 expression by MM cells was upregulated in hypoxic conditions and that stable knockdown of hypoxia inducible factor-1α significantly downregulated its expression. Therefore, we performed Gal-1 inhibition using lentivirus transfection of shRNA anti-Gal-1 in human myeloma cell lines (HMCLs), and showed that its suppression modified transcriptional profiles in both hypoxic and normoxic conditions. Interestingly, Gal-1 inhibition in MM cells downregulated proangiogenic genes, including MMP9 and CCL2, and upregulated the antiangiogenic ones SEMA3A and CXCL10. Consistently, Gal-1 suppression in MM cells significantly decreased their proangiogenic properties in vitro. This was confirmed in vivo, in two different mouse models injected with HMCLs transfected with anti-Gal-1 shRNA or the control vector. Gal-1 suppression in both models significantly reduced tumor burden and microvascular density as compared with the control mice. Moreover, Gal-1 suppression induced smaller lytic lesions on X-ray in the intratibial model. Overall, our data indicate that Gal-1 is a new potential therapeutic target in MM blocking angiogenesis.Leukemia advance online publication, 17 June 2016; doi:10.1038/leu.2016.137.

Original languageEnglish (US)
JournalLeukemia
DOIs
StateAccepted/In press - Jun 17 2016

Fingerprint

Galectin 1
Multiple Myeloma
Growth
Small Interfering RNA
Down-Regulation
Hypoxia-Inducible Factor 1
Cell Line
Lentivirus
Tumor Burden
Transfection
Publications
Leukemia
X-Rays

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Storti, P., Marchica, V., Airoldi, I., Donofrio, G., Fiorini, E., Ferri, V., ... Giuliani, N. (Accepted/In press). Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo. Leukemia. https://doi.org/10.1038/leu.2016.137

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo. / Storti, P.; Marchica, V.; Airoldi, I.; Donofrio, G.; Fiorini, E.; Ferri, V.; Guasco, D.; Todoerti, K.; Silbermann, R.; Anderson, J. L.; Zhao, W.; Agnelli, L.; Bolzoni, M.; Martella, E.; Mancini, C.; Campanini, N.; Noonan, D. M.; Petronini, P. G.; Neri, A.; Aversa, F.; Roodman, G. David; Giuliani, N.

In: Leukemia, 17.06.2016.

Research output: Contribution to journalArticle

Storti, P, Marchica, V, Airoldi, I, Donofrio, G, Fiorini, E, Ferri, V, Guasco, D, Todoerti, K, Silbermann, R, Anderson, JL, Zhao, W, Agnelli, L, Bolzoni, M, Martella, E, Mancini, C, Campanini, N, Noonan, DM, Petronini, PG, Neri, A, Aversa, F, Roodman, GD & Giuliani, N 2016, 'Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo', Leukemia. https://doi.org/10.1038/leu.2016.137
Storti, P. ; Marchica, V. ; Airoldi, I. ; Donofrio, G. ; Fiorini, E. ; Ferri, V. ; Guasco, D. ; Todoerti, K. ; Silbermann, R. ; Anderson, J. L. ; Zhao, W. ; Agnelli, L. ; Bolzoni, M. ; Martella, E. ; Mancini, C. ; Campanini, N. ; Noonan, D. M. ; Petronini, P. G. ; Neri, A. ; Aversa, F. ; Roodman, G. David ; Giuliani, N. / Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo. In: Leukemia. 2016.
@article{bdd8176a8a40445d813a94c0a6453513,
title = "Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo",
abstract = "Galectin-1 (Gal-1) is involved in tumoral angiogenesis, hypoxia and metastases. Actually the Gal-1 expression profile in multiple myeloma (MM) patients and its pathophysiological role in MM-induced angiogenesis and tumoral growth are unknown. In this study, we found that Gal-1 expression by MM cells was upregulated in hypoxic conditions and that stable knockdown of hypoxia inducible factor-1α significantly downregulated its expression. Therefore, we performed Gal-1 inhibition using lentivirus transfection of shRNA anti-Gal-1 in human myeloma cell lines (HMCLs), and showed that its suppression modified transcriptional profiles in both hypoxic and normoxic conditions. Interestingly, Gal-1 inhibition in MM cells downregulated proangiogenic genes, including MMP9 and CCL2, and upregulated the antiangiogenic ones SEMA3A and CXCL10. Consistently, Gal-1 suppression in MM cells significantly decreased their proangiogenic properties in vitro. This was confirmed in vivo, in two different mouse models injected with HMCLs transfected with anti-Gal-1 shRNA or the control vector. Gal-1 suppression in both models significantly reduced tumor burden and microvascular density as compared with the control mice. Moreover, Gal-1 suppression induced smaller lytic lesions on X-ray in the intratibial model. Overall, our data indicate that Gal-1 is a new potential therapeutic target in MM blocking angiogenesis.Leukemia advance online publication, 17 June 2016; doi:10.1038/leu.2016.137.",
author = "P. Storti and V. Marchica and I. Airoldi and G. Donofrio and E. Fiorini and V. Ferri and D. Guasco and K. Todoerti and R. Silbermann and Anderson, {J. L.} and W. Zhao and L. Agnelli and M. Bolzoni and E. Martella and C. Mancini and N. Campanini and Noonan, {D. M.} and Petronini, {P. G.} and A. Neri and F. Aversa and Roodman, {G. David} and N. Giuliani",
year = "2016",
month = "6",
day = "17",
doi = "10.1038/leu.2016.137",
language = "English (US)",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo

AU - Storti, P.

AU - Marchica, V.

AU - Airoldi, I.

AU - Donofrio, G.

AU - Fiorini, E.

AU - Ferri, V.

AU - Guasco, D.

AU - Todoerti, K.

AU - Silbermann, R.

AU - Anderson, J. L.

AU - Zhao, W.

AU - Agnelli, L.

AU - Bolzoni, M.

AU - Martella, E.

AU - Mancini, C.

AU - Campanini, N.

AU - Noonan, D. M.

AU - Petronini, P. G.

AU - Neri, A.

AU - Aversa, F.

AU - Roodman, G. David

AU - Giuliani, N.

PY - 2016/6/17

Y1 - 2016/6/17

N2 - Galectin-1 (Gal-1) is involved in tumoral angiogenesis, hypoxia and metastases. Actually the Gal-1 expression profile in multiple myeloma (MM) patients and its pathophysiological role in MM-induced angiogenesis and tumoral growth are unknown. In this study, we found that Gal-1 expression by MM cells was upregulated in hypoxic conditions and that stable knockdown of hypoxia inducible factor-1α significantly downregulated its expression. Therefore, we performed Gal-1 inhibition using lentivirus transfection of shRNA anti-Gal-1 in human myeloma cell lines (HMCLs), and showed that its suppression modified transcriptional profiles in both hypoxic and normoxic conditions. Interestingly, Gal-1 inhibition in MM cells downregulated proangiogenic genes, including MMP9 and CCL2, and upregulated the antiangiogenic ones SEMA3A and CXCL10. Consistently, Gal-1 suppression in MM cells significantly decreased their proangiogenic properties in vitro. This was confirmed in vivo, in two different mouse models injected with HMCLs transfected with anti-Gal-1 shRNA or the control vector. Gal-1 suppression in both models significantly reduced tumor burden and microvascular density as compared with the control mice. Moreover, Gal-1 suppression induced smaller lytic lesions on X-ray in the intratibial model. Overall, our data indicate that Gal-1 is a new potential therapeutic target in MM blocking angiogenesis.Leukemia advance online publication, 17 June 2016; doi:10.1038/leu.2016.137.

AB - Galectin-1 (Gal-1) is involved in tumoral angiogenesis, hypoxia and metastases. Actually the Gal-1 expression profile in multiple myeloma (MM) patients and its pathophysiological role in MM-induced angiogenesis and tumoral growth are unknown. In this study, we found that Gal-1 expression by MM cells was upregulated in hypoxic conditions and that stable knockdown of hypoxia inducible factor-1α significantly downregulated its expression. Therefore, we performed Gal-1 inhibition using lentivirus transfection of shRNA anti-Gal-1 in human myeloma cell lines (HMCLs), and showed that its suppression modified transcriptional profiles in both hypoxic and normoxic conditions. Interestingly, Gal-1 inhibition in MM cells downregulated proangiogenic genes, including MMP9 and CCL2, and upregulated the antiangiogenic ones SEMA3A and CXCL10. Consistently, Gal-1 suppression in MM cells significantly decreased their proangiogenic properties in vitro. This was confirmed in vivo, in two different mouse models injected with HMCLs transfected with anti-Gal-1 shRNA or the control vector. Gal-1 suppression in both models significantly reduced tumor burden and microvascular density as compared with the control mice. Moreover, Gal-1 suppression induced smaller lytic lesions on X-ray in the intratibial model. Overall, our data indicate that Gal-1 is a new potential therapeutic target in MM blocking angiogenesis.Leukemia advance online publication, 17 June 2016; doi:10.1038/leu.2016.137.

UR - http://www.scopus.com/inward/record.url?scp=84975122307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975122307&partnerID=8YFLogxK

U2 - 10.1038/leu.2016.137

DO - 10.1038/leu.2016.137

M3 - Article

C2 - 27311934

AN - SCOPUS:84975122307

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -